Human IL-20 Antibody - Fletikumab Biosimilar

Human IgG4 (S228P) - CAS #1357158-22-5

ABOUT

Anti-human IL-20 - Fletikumab biosimilar - CAS #1357158-22-5

Anti-hIL-20-hIgG4 (S228P) is a biosimilar antibody of Fletikumab, a human interleukin-20 (IL-20) antibody that inhibits IL-20 signaling. This monoclonal antibody (mAb) has undergone clinical investigations for the treatment of rheumatoid arthritis and psoriasis.

More details More details

 

Anti-hIL-20-hIgG4 (S228P) comprises the variable region and the human IgG4 (S228P) constant region of Fletikumab to achieve low/no effector function.

This mAb can be used together with HEK-Blue™ IL-19/IL-20 cells for screening and neutralization assays to inhibit IL-20 signaling induced by recombinant human IL-20 (see figure).

 

Key features

  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct was verified.
  • The absence of endotoxins is determined using the EndotoxDetect™ assay.

All products are for research use only, and not for human or veterinary use.

Binding of anti-hIL-20 Fletikumab
Binding of anti-hIL-20 Fletikumab

SPECIFICATIONS

Specifications

Target

IL-20

Target species

Human

Applications

Neutralization assay (tested)

ELISA

Species
Human
Isotype
hIgG4 (S228P)
kappa
Recommended isotype control
Human IgG4 (S228P) Isotype Control Antibody
Clone
Fletikumab
CAS number
1357158-22-5
Synonyms
NNC0109-0012
Molecular weight
146.5 kDa
Tag
Tag-free
Source
CHO cells
Production details
Animal-free
Purification
Protein A
Formulation buffer

Sodium phosphate buffer, glycine, saccharose, stabilizing agents

Preservative
Azide-free
Purity
≥95% (SDS-PAGE)
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hIL-20-hIgG4 (S228P)
  • Cat code: 
    hil20-mab14
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Fletikumab and IL-20 background

Fletikumab is a fully human IgG4 monoclonal antibody designed to target interleukin 20 (IL-20), a pro-inflammatory cytokine involved in various inflammatory diseases. By binding to IL-20, Fletikumab inhibits the cytokine's interaction with its receptor, thereby modulating inflammatory responses [1]. 

IL-20 is a member of the IL-10 cytokine family and plays a significant role in immune responses, particularly in the regulation of inflammatory processes [1-2]. It signals through two receptors, which are shared with IL-19 and IL-24. The IL-20 type I receptor is composed of the IL-20Rα (aka IL-20R1) and IL-20Rβ (aka IL-20R2) chains, and binds IL-19, IL-20, and IL-24. The IL-20 type II receptor is composed of the IL-22Rα1 (aka IL-22R1) and IL-20Rβ chains and binds IL-20 and IL-24 [2-3]. 

IL-20 is upregulated in many human diseases, such as psoriasis, inflammatory bowel disease, and rheumatoid arthritis (RA) [2]. Fletikumab has undergone clinical investigations for the treatment of rheumatoid arthritis and psoriasis [2].

 

References:

1. Kragstrup TW, et al., 2018. The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis. Front Immunol. 9:2226. 
2. Ouyang W, O'Garra A., 2019. IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation. Immunity.50(4):871-891
3. Caparrós E, Francés R., 2018. The Interleukin-20 Cytokine Family in Liver Disease. Front Immunol. 9:1155. 

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?